Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 1/20 | 0.51 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.51 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127652 | 0.91 | BMPR1B (0.51) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL3134088 | 0.76 | BMPR1B (0.49) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL3134043 | 0.74 | BMPR1B (0.56) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL3134067 | 0.73 | HRH3 (0.48) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL29973108 | 0.70 | HRH3 (0.69) | EPHX2HRH3 | |
| SCHEMBL4256813 | 0.69 | EPHX2 (0.61) | EPHX2 | |
| SCHEMBL28678935 | 0.68 | MAOB (0.65) | HRH3 | |
| SCHEMBL29370348 | 0.68 | BMPR1B (1.00) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL19806967 | 0.68 | BMPR1B (1.00) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL27896953 | 0.68 | HRH3 (0.76) | HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | BMPR1B 3886/4885BMPR1A 3462/4885TGFBR1 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.